List of Excipients in Branded Drug TRIENTINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceutials	TRIENTINE HYDROCHLORIDE	trientine hydrochloride	68682-212	GELATIN
Oceanside Pharmaceutials	TRIENTINE HYDROCHLORIDE	trientine hydrochloride	68682-212	STEARIC ACID
Oceanside Pharmaceutials	TRIENTINE HYDROCHLORIDE	trientine hydrochloride	68682-212	TITANIUM DIOXIDE

Generic Drugs Containing TRIENTINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Lannett Company Inc	trientine hydrochloride	0527-4068	FD&C YELLOW NO. 6
Lannett Company Inc	trientine hydrochloride	0527-4068	FERROSOFERRIC OXIDE
Lannett Company Inc	trientine hydrochloride	0527-4068	GELATIN
Lannett Company Inc	trientine hydrochloride	0527-4068	POTASSIUM HYDROXIDE

What are the Most Frequently-Used Excipients in TRIENTINE HYDROCHLORIDE?

# Of NDCs	Excipient
3	ALCOHOL
4	AMMONIA
3	BUTYL ALCOHOL
1	D&C RED NO. 28

Trientine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Trientine hydrochloride is a clinically established copper-chelating therapy for Wilson disease, but its commercial opportunity is concentrated in formulation quality, supply reliability, pediatric usability, and differentiated generic delivery. The core excipient strategy should control moisture, trace metals, oxidation, capsule or tablet compatibility, and administration-related interactions with iron, calcium, zinc, and other polyvalent cations. The most attractive opportunities are low-cost generic capsules, improved pediatric formulations, metal-controlled packaging, and alternative oral dosage forms with demonstrated stability.

What is trientine hydrochloride used for?

Trientine is an orally administered copper chelator used to reduce copper accumulation in patients with Wilson disease. The drug binds copper and promotes urinary excretion. FDA-approved products and international products use different trientine salts, including trientine hydrochloride, trientine dihydrochloride, and trientine tetrahydrochloride.

Wilson disease is a rare inherited disorder caused primarily by pathogenic variants in ATP7B. Treatment is chronic and may continue for life. Patients commonly require repeated daily dosing, creating a commercial premium for products that improve adherence, swallowing, storage, and dosing convenience.

Product	Salt or active form	Dosage form	Regulatory market
Syprine	Trientine hydrochloride	250 mg capsules	United States
Generic trientine hydrochloride	Trientine hydrochloride	Capsules	United States and other markets
Cuvrior	Trientine tetrahydrochloride	Tablets	United States
Cuprior	Trientine tetrahydrochloride	Tablets	European Union and other markets
Cufence	Trientine dihydrochloride	Capsules	European Union and other markets

Cuvrior was approved by the FDA in 2022 for adults and pediatric patients at least 12 years old who are intolerant to penicillamine, or who cannot use penicillamine because of clinical considerations [1]. Syprine is an older reference product containing trientine hydrochloride capsules [2].

What excipients are used in trientine products?

Commercial trientine products use conventional capsule and tablet excipients, but the formulation environment is unusually sensitive to elemental impurities and metal-containing materials.

Trientine hydrochloride capsule excipients

Syprine is supplied as a hard capsule containing 250 mg of trientine hydrochloride. Public labeling identifies capsule-shell components and conventional pharmaceutical excipients, including gelatin and titanium dioxide, with product-specific colorants and processing materials depending on the market and presentation [2].

Generic manufacturers may use:

• Gelatin or hypromellose capsule shells
• Microcrystalline cellulose
• Crospovidone or croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate or stearic acid
• Titanium dioxide
• Approved capsule colorants
• Low-moisture packaging systems

The formulation objective is not maximum excipient complexity. A short excipient list reduces compatibility risk, analytical burden, and variability between suppliers.

Trientine tetrahydrochloride tablet excipients

Cuvrior uses a film-coated tablet platform. Public product information identifies a formulation based on mannitol, crospovidone, colloidal anhydrous silica, and stearic acid in the tablet core, with film-coating materials that include hypromellose and colorants [1,3].

This platform illustrates a commercially relevant approach:

• Mannitol provides bulk and a relatively low-reactivity diluent.
• Crospovidone supports disintegration without introducing a metal ion.
• Colloidal silicon dioxide improves powder flow.
• Stearic acid supports lubrication.
• Hypromellose provides film formation.
• Iron oxide colorants require tight elemental impurity controls because iron is a relevant chelatable metal.

The use of a tablet rather than a capsule can improve dose uniformity, permit film coating, and support visual differentiation. The tradeoff is greater process development complexity and the need to demonstrate robust dissolution across manufacturing scale.

Which excipients are most suitable for trientine hydrochloride?

The preferred excipients are chemically inert, low in trace metals, low in moisture, and compatible with direct compression or low-shear encapsulation.

Preferred excipient classes

Function	Preferred options	Main rationale
Diluent	Mannitol, microcrystalline cellulose	Low reactivity and established oral safety
Disintegrant	Crospovidone, croscarmellose sodium	Rapid breakup without adding polyvalent metals
Glidant	Colloidal silicon dioxide	Supports flow at low concentration
Lubricant	Stearic acid, selected low-metal magnesium stearate	Supports processing; requires elemental impurity control
Binder	Low-substituted hydroxypropyl cellulose, povidone where justified	Supports granulation or tablet strength
Capsule shell	Hypromellose or gelatin	Commercially established; moisture profile must be controlled
Film coat	Hypromellose-based coating	Protects the core and improves identification
Taste masking	Polymer coating or multiparticulate barrier	Relevant for liquid, chewable, or pediatric products

Excipients requiring caution

Calcium salts, iron salts, zinc salts, and other mineral-containing materials are poor choices for a trientine formulation unless their role is essential and the interaction is characterized. Trientine is intended to bind copper and can interact with other metal ions. FDA labeling instructs separation of trientine from mineral supplements and other products containing iron, zinc, calcium, or magnesium [1,2].

Magnesium stearate is widely used and is not automatically unsuitable. The issue is specification control, not simply the excipient name. Suppliers should provide limits for elemental impurities and demonstrate that the lubricant does not alter assay, dissolution, or stability.

Colorants containing iron oxide may be acceptable in a coated tablet, but they increase the need for a documented elemental impurity risk assessment under ICH Q3D. A color-free capsule may offer a simpler control strategy.

How should a trientine hydrochloride formulation control moisture and metals?

Moisture and metal control should be treated as central critical quality attributes.

Trientine is a polyamine with multiple nitrogen atoms capable of metal coordination. The active ingredient can therefore interact with trace metals introduced through excipients, manufacturing equipment, water, pigments, or packaging. The formulation program should include:

1. Elemental impurity mapping for copper, iron, nickel, zinc, cobalt, lead, and other ICH Q3D elements.
2. Supplier qualification for excipients and capsule shells.
3. Testing of raw materials and finished product by ICP-MS or an equivalent validated method.
4. Water activity and loss-on-drying controls.
5. Moisture sorption studies for the active and blend.
6. Packaging studies under high humidity and accelerated conditions.
7. Compatibility testing with stainless-steel contact surfaces and manufacturing equipment.
8. Evaluation of assay, related substances, dissolution, capsule brittleness, and tablet hardness over time.

Aluminum or high-barrier blister packaging may be commercially preferable to high-density polyethylene bottles where moisture ingress is a material risk. A desiccant bottle can be less expensive, but it introduces child-resistant closure, desiccant migration, and in-use stability considerations.

A low-moisture hypromellose capsule can be attractive for a generic product, but the shell must be tested for brittleness, locking performance, dissolution, and long-term storage. Gelatin capsules may provide a familiar platform but have greater dependence on humidity conditions.

What formulation patents protect trientine products?

The principal commercial distinction is between older trientine hydrochloride capsule products and newer tablet products based on different trientine salts.

Patent category	Commercial relevance
Active ingredient and salt patents	May protect a particular salt, purity profile, or solid form
Tablet formulation patents	May cover excipient combinations, compression properties, coating, or dissolution
Method-of-use patents	May cover treatment of Wilson disease, patient populations, or dosing regimens
Manufacturing patents	May cover crystallization, purification, granulation, or impurity reduction
Packaging patents	May cover moisture-control systems or stability-enhancing containers

Older composition patents covering trientine hydrochloride are likely to have limited remaining life because the compound and Syprine have been marketed for decades. Newer patent risk is more likely to arise from formulation, salt, manufacturing, or dosing claims tied to products such as Cuvrior.

A freedom-to-operate review should distinguish the molecule from the approved product. A generic trientine hydrochloride capsule may avoid patents directed specifically to trientine tetrahydrochloride tablets, while still facing method-of-use or manufacturing claims. Patent scope must be assessed claim by claim in each jurisdiction.

When does trientine hydrochloride lose exclusivity?

Trientine hydrochloride itself is an old active ingredient. Its principal commercial barriers are therefore regulatory approval, manufacturing quality, supply continuity, and market access rather than basic compound exclusivity.

For Syprine and generic trientine hydrochloride:

• The original active-ingredient exclusivity period has expired.
• Any remaining barriers are product-specific patents, regulatory exclusivities, litigation settlements, or market-access restrictions.
• Generic entry can occur through an abbreviated application pathway if the applicant demonstrates pharmaceutical equivalence, bioequivalence, and applicable labeling requirements.

For Cuvrior:

• FDA approval occurred in 2022.
• The product may have pediatric exclusivity, orphan-drug exclusivity, listed patents, or other protections that must be assessed through current FDA and USPTO records.
• Cuvrior’s protection is more likely to be relevant to trientine tetrahydrochloride tablets than to a separate trientine hydrochloride capsule.

Orphan-drug exclusivity generally prevents FDA approval of the same drug for the same disease or condition for seven years from approval, subject to statutory exceptions [4]. Orphan exclusivity does not necessarily block a different salt, formulation, or legally distinct product in every circumstance.

What is the Orange Book status of trientine hydrochloride?

Syprine is an FDA-approved prescription product and has been listed in FDA drug-product databases. Cuvrior is listed as an approved product under NDA 215559, with trientine tetrahydrochloride as the active ingredient [1].

Orange Book analysis should focus on:

• Listed patents for the reference product.
• Patent expiration dates.
• Pediatric exclusivity.
• Orphan exclusivity.
• Whether a generic applicant can file Paragraph IV certification.
• Whether the proposed generic uses the same active moiety and dosage form.
• Whether labeling must carve out a patented method of use.

The relevant legal distinction is that a Paragraph IV certification challenges the validity, enforceability, or infringement of a listed patent. A Paragraph IV filing can trigger patent litigation within 45 days of notice and may create a 30-month stay of approval under the Hatch-Waxman framework [5].

Which companies are challenging trientine products?

Generic competition is more likely around trientine hydrochloride capsules than around branded trientine tetrahydrochloride tablets. Generic applicants typically compete on:

• Capsule strength and count size
• Wholesale acquisition cost
• Distributor supply
• State substitution
• Back-order avoidance
• Authorized-generic or specialty-pharmacy arrangements

Publicly available FDA records should be used to identify current ANDA approvals, tentative approvals, listed patents, and Paragraph IV litigation. A definitive current list of challengers requires a live review of FDA, USPTO, PACER, and Orange Book records.

How strong is the patent estate for trientine hydrochloride?

The patent estate for the old hydrochloride capsule platform is generally weaker than the estate for a recently approved, reformulated tablet.

Older capsule platform

Strengths include:

• Established clinical use
• Straightforward manufacturing
• Familiar regulatory pathway
• Potentially broad supplier availability

Weaknesses include:

• Limited compound-patent life
• Generic substitution risk
• Few durable formulation barriers
• Price erosion after multiple entrants

Newer tablet or alternative-salt platform

Strengths include:

• Potentially later-expiring formulation or manufacturing claims
• Tablet-specific performance characteristics
• Differentiated dosing presentation
• Opportunities for pediatric and adherence claims

Weaknesses include:

• Greater dependence on specific excipient combinations
• Higher development and scale-up costs
• Potential design-around options
• Patent claims that may be narrow or vulnerable if obviousness is established

The most defensible IP position would combine a differentiated salt or solid form with a measurable stability, dissolution, or impurity-control advantage. A patent directed only to a routine capsule excipient combination would generally face higher design-around risk.

What commercial opportunities exist for trientine excipients?

Low-metal generic capsules

The clearest near-term opportunity is a generic capsule with:

• A short excipient list
• Verified low elemental impurities
• High-barrier packaging
• Stable supply of capsule shells
• Competitive pricing
• Consistent dissolution and assay

The product can be differentiated through reliable availability rather than novel pharmacology.

Pediatric formulations

Pediatric patients may have difficulty swallowing capsules or tablets. A liquid, powder-for-reconstitution, mini-tablet, or sprinkle formulation could address this need.

The principal technical problems are:

• Strong or unpleasant taste
• Dose uniformity at low volumes
• Metal contamination from flavor systems and colorants
• Shorter in-use stability
• Interaction with food and mineral-containing vehicles
• Packaging and dosing-device accuracy

A ready-to-use liquid may carry high development and stability costs. A dry powder or dispersible mini-tablet could provide a better balance between usability and shelf life.

Modified-release and enteric delivery

Modified-release products may reduce dosing burden or improve gastrointestinal tolerability, but the commercial rationale is less certain because trientine is administered under strict food-separation instructions. Any modified-release concept would require evidence that copper chelation is preserved and that food effects do not create clinically meaningful variability.

Enteric coating could protect the active from gastric conditions or alter tolerability, but it creates a more complex regulatory bridge to an immediate-release reference product.

Packaging and adherence systems

A premium product could use:

• Unit-dose aluminum blisters
• Calendar packaging
• Integrated desiccant systems
• Tamper-evident child-resistant bottles
• Dosing reminders
• Separate storage instructions for mineral supplements

Packaging patents may be narrower than formulation patents, but packaging can produce a practical market advantage in a chronic orphan-disease population.

How does trientine compare with penicillamine and zinc therapy?

Attribute	Trientine	Penicillamine	Zinc salts
Primary role	Copper chelation	Copper chelation	Reduces intestinal copper absorption
Tolerability	Often used when penicillamine is not tolerated	Significant adverse-effect burden in some patients	Different tolerability and adherence issues
Food restrictions	Important	Important	Important
Formulation opportunity	Capsules, tablets, pediatric products	Capsules and tablets	Tablets, capsules, compounded products
Generic competition	High for older capsule products	Established	Established
Differentiation path	Stability, pediatric usability, supply	Tolerability and dosing	Adherence and administration

Trientine’s commercial position benefits from its use as an alternative for patients who cannot tolerate penicillamine. The market is small, but treatment is chronic and medically necessary, which can support specialty-pharmacy distribution and premium pricing for dependable supply.

What manufacturing and IP barriers affect trientine hydrochloride?

The main manufacturing barriers are control of:

• Active-substance purity
• Residual solvents
• Water content
• Related substances
• Trace metals
• Blend uniformity
• Capsule fill weight
• Dissolution
• Packaging moisture ingress

A manufacturer with a qualified low-metal supply chain may have a stronger practical position than a company holding a narrow formulation patent. The most valuable manufacturing know-how may involve purification, crystallization, drying, and control of metal contamination.

Geographic coverage should be evaluated separately:

• United States: FDA approval, Orange Book patents, ANDA and Paragraph IV strategy
• European Union: centralized or national authorization, Supplementary Protection Certificate considerations, and country-specific reimbursement
• Japan: PMDA requirements and local market access
• Emerging markets: local registration, pricing controls, and counterfeit-risk management

A global product should avoid unnecessary differences in capsule colorants, excipient suppliers, and packaging formats. A common core formula with market-specific labeling and pack sizes can reduce regulatory maintenance.

What generic launch scenarios exist for trientine hydrochloride?

Scenario 1: Single low-cost capsule entrant

This is the fastest erosion scenario. A single approved generic can pressure reimbursement and reduce brand share, but supply may remain concentrated.

Scenario 2: Multiple capsule entrants

Several approved generics can produce substantial price compression. Brand retention may depend on patient support, specialty-pharmacy contracts, and supply reliability.

Scenario 3: Generic capsule plus differentiated tablet

A standard capsule can compete on price while a tablet competes on convenience, pediatric use, or adherence. This creates segmentation rather than immediate substitution across all patients.

Scenario 4: Pediatric or liquid entrant

A child-friendly product can command a premium if it demonstrates stability, accurate dosing, and acceptable taste. Regulatory bridging and clinical usability data become the main barriers.

What litigation and settlement issues matter?

Relevant litigation questions include:

• Whether a generic applicant filed Paragraph IV certifications.
• Whether the patent holder sued within 45 days.
• Whether FDA approval was stayed for 30 months.
• Whether the parties entered a license or delayed-entry settlement.
• Whether the agreement was submitted to the FTC under applicable reporting requirements.
• Whether the settlement permits an authorized generic or early licensed entry.

No broad conclusion about current trientine litigation should be drawn from historical patent records alone. Current docket and Orange Book data determine whether a live challenge affects launch timing.

Key Takeaways

• Trientine hydrochloride is an established copper-chelating therapy with limited basic compound-patent protection.
• The strongest formulation strategy is a low-moisture, low-metal capsule or tablet using a short excipient list.
• Calcium, iron, zinc, magnesium, and metal-containing colorants require specific compatibility and elemental impurity controls.
• Generic capsules face price and substitution pressure, while pediatric, liquid, mini-tablet, and adherence-focused products offer higher-value opportunities.
• Cuvrior’s trientine tetrahydrochloride tablet platform should be analyzed separately from older trientine hydrochloride capsules.
• Manufacturing know-how, supplier qualification, packaging, and reliable distribution may create stronger commercial barriers than narrow excipient patents.
• Paragraph IV risk, Orange Book listings, orphan exclusivity, and settlement terms determine the timing of competitive entry.

FAQs

Is trientine hydrochloride the same as trientine tetrahydrochloride?

No. They are different salts of the same active moiety. Salt-specific formulation, dosing, equivalence, and patent analysis are required.

Can magnesium stearate be used in trientine hydrochloride capsules?

Yes, but the material should be qualified for elemental impurities and evaluated for compatibility, assay, dissolution, and stability.

What is the best excipient for a pediatric trientine product?

No single excipient is universally preferred. A pediatric product should prioritize low-metal materials, taste control, dose uniformity, and long in-use stability. Mannitol, crospovidone, hypromellose, and selected polymer coatings are plausible starting platforms.

Are trientine products eligible for generic substitution?

Substitution depends on the specific approved product, dosage form, active salt, therapeutic-equivalence rating, state law, and pharmacy policy. A trientine hydrochloride capsule should not be presumed automatically substitutable for a trientine tetrahydrochloride tablet.

What is the most defensible commercial differentiation for trientine?

The strongest near-term differentiation is a stable, low-metal product with dependable supply, child-friendly administration, and packaging that supports chronic adherence.

References

1. U.S. Food and Drug Administration. (2022). Cuvrior prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Syprine prescribing information. FDA.

3. European Medicines Agency. (2022). Cuprior: EPAR product information. EMA.

4. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.